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Gut microbiotaNot much is known about the initial events leading to the development of the central nervous sys-
tem (CNS)-speciﬁc autoimmune disorder Multiple Sclerosis (MS). Environmental factors are sus-
pected to trigger the pathogenic events in people with genetic disease susceptibility. Historically,
many infectious microbes were linked to MS, but no infection has ever been demonstrated to be
the cause of the disease. Recent emerging evidence from animal models of MS suggests a causal link
with resident commensal bacteria. Microbial organisms may trigger the activation of CNS-speciﬁc,
auto-aggressive lymphocytes either through molecular mimicry or via bystander activation. In addi-
tion, several gut microbial metabolites and bacterial products may interact with the immune system
to modulate CNS autoimmunity.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Microbes are the foundation of all life. We, as humans, are sur-
rounded by a myriad of microbes which perform plentiful tasks,
crucial for our survival. Numerically, we are a tiny fraction com-
pared to the microorganisms that populate every conceivable hab-
itat in the world, ranging from exotic marine ﬂoors to our body’s
mucosal surfaces [1]. From our ‘health’ perspective, microbes can
be loosely classiﬁed into harmless, beneﬁcial or pathogenic. Our
encounters with these microbes are variable and complex. In case
infectious pathogens ﬁnd a way to inﬁltrate our body, they pose a
great threat to our life. To counteract these pathogenic microor-
ganisms, our immune system is equipped with an arsenal of
receptors as well as soluble molecules, but unfortunately it is not
fool-proof. Microbes can induce strong immune responses, which
are mainly targeting antigens encoded by the infecting organism,
at the same time, they are capable of triggering secondary
responses against self-antigens, resulting in autoimmunity.
In recent years, there has been a spur into the research of ben-
eﬁcial microbes that reside in our body. In this review, we discuss
selected examples of discoveries connecting the microbes with the
central nervous system autoimmune diseases with the emphasis
on data relevant to the emerging relationship between the gut mic-
robiota and neuroinﬂammation.2. CNS-speciﬁc autoimmunity: interactions between the
immune and the central nervous system
Evolution provided us with the two most complex physiological
systems – the nervous system and the immune system. For long, it
has been thought that these two systems are secluded from inter-
actions, but it is becoming clear that the communication between
them is of fundamental importance for maintaining our body’s
physiology. For instance, the central nervous system (CNS) controls
the immune system throughmany hormonal as well as neural acti-
vation pathways [2]. The immune system is kept in check by the
nervous system through the release of neurotransmitters via sym-
pathetic and parasympathetic innervations of immune organs [3].
On the other hand, peripheral immune activation during infections
lead to behavioral alterations through soluble cytokine mediators,
termed the sickness syndrome [4].
The CNS was considered to be an immune privileged organ
mainly because it is spatially contained in a closed compartment
secluded from the circulation by physical barriers, such as the
blood brain barrier and the blood cerebrospinal ﬂuid barrier
[5,6]. The lack of lymphatic drainage, the lack of major histocom-
patibility complex (MHC) molecule expression by parenchymal
cells as well as the anti-inﬂammatory environment of the CNS
were, in addition, accounted for its immune privileged status
[5,7]. Nevertheless, immune cells are able to survey the healthy
CNS, challenging this ‘‘immune privilege’’ dogma [8] and upon
infection or traumatic injury immune cells are actively recruited
to the CNS [5]. In addition, the CNS is susceptible to immune
attacks resulting in neuroinﬂammation, which is commonly
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Neuromyelitis optica (NMO) [9,10].
MS is the most common autoimmune disease of the CNS, with
sharply demarcated demyelinating plaques [11]. The demyelinated
lesions are usually located in areas of the CNS white matter
together with features that are compatible with inﬂammatory pro-
cesses [9]. Besides the white matter involvement, recent reports
show that cortical demyelination is frequently observed in early
MS lesions [12]. NMO, also known as Devic’s disease, is a CNS-
speciﬁc autoimmune disease featuring demyelination in the optic
nerve and spinal cord. NMO was classiﬁed as a subset of MS until
the identiﬁcation of aquaporin-4-speciﬁc antibodies [13]. In addi-
tion to these classical CNS-speciﬁc autoimmune diseases, there
are infectious as well as neurodegenerative conditions affecting
the nervous system and featuring inﬂammatory components [14].
Despite intense research over decades, the origin of CNS direc-
ted autoimmune responses is unclear. There are two schools of
thoughts about the initiation of CNS autoimmune responses: (a)
Changes in the central nervous system take place and as a conse-
quence of these changes immune cells inﬁltrate the CNS [15]. (b)
Autoimmune responses are initiated in the periphery and neurode-
generation follows [16]. There is no formal evidence supporting
one of these hypotheses. It is more likely that both events take
place at various levels during disease pathogenesis.
3. Infectious pathogens as triggers of CNS autoimmunity
For a long time, viral as well as bacterial infections were sus-
pected to be the triggers of MS. Microbial pathogens may de-regu-
late immune responses, which could predispose an individual to
autoimmune pathologies. Viruses that induce persistent infections
in humans (like herpes viruses or retroviruses) were widely stud-
ied as initiators of MS. Human herpes virus 6 (HHV-6) and
Epstein–Barr virus (EBV) were among the leading candidates.
HHV-6, which strikes usually in early childhood, is ubiquitous with
a seropositivity of more than 90% in the general population. Studies
could detect HHV-6 infected oligodendrocytes in MS lesions [17]
and showed increased anti-HHV-6 IgM antibody titers in cerebro-
spinal ﬂuid of relapsing-remitting MS patients [18]. Furthermore,
epidemiological studies revealed an increased risk for MS in EBV-
seropositive individuals [19]. While 95% of the general population
is seropositive, 100% of MS patients were positive for serum EBV
antibodies [20]. In addition to being a candidate for triggering
CNS-speciﬁc autoimmunity, few studies suggested that viral infec-
tions may also be responsible for relapses [21]. Experimental stud-
ies in animal models with the infection of Theiler’s murine
encephalomyelitis virus (TMEV) or mouse hepatitis virus (MHV),
which induced demyelination resembling many features of MS,
further support the theory of infectious pathogens as triggers of
MS [22]. Besides viruses, bacterial pathogens were considered as
initiators of MS, although the data is controversial. Chlamydia
pneumonia, a Gram-negative intracellular bacterium, has been
associated with MS in one study [23] whereas another study was
not able to replicate this ﬁnding [24]. Although many infectious
pathogens were suspected to induce MS, they often failed to stand
the test of time.Table 1
Examples of cross-reactive epitopes of myelin and microbial antigens.
Antigen T cell source Mimicry microbial antigen
MBP85–99 Human Human papillomavirus type 7, L2 prot
MBP85–99 Human EBV, DNA polymerase Herpes simplex
MBP66–75 Human Hepatitis B virus (HBV) polymerase 58
MBP85–99 Human EBV 627–641
MOG35–55 Rat Human cytomegalovirus major capsid
AQP461–80 Human Clostridium perfringens adenosine triphPathogenic microbes can trigger CNS-speciﬁc autoimmune
responses either via direct or via indirect mechanisms. Two possi-
bilities of how microbes can initiate autoimmunity have been
envisaged: molecular mimicry and bystander activation [25,26].
The original concept of molecular mimicry refers to the cross-rec-
ognition of a self- and a microbial antigen by the same lymphocyte
due to sequence homologies between the two antigens [27,28].
Fujinami and Oldstone showed that certain microbial epitopes
potentially cross-react with the human myelin basic protein
(MBP) [29]. Subsequent investigations by several research groups
led to the identiﬁcation of putative mimicry peptides that may
activate CNS-speciﬁc autoimmune responses in humans as well
as experimental animals (Table 1). However, despite all the reports
of molecular mimicry, establishing a causal relationship between
an infectious pathogen and auto-aggressive lymphocytes in MS
remained impossible.
A strong immune response against a pathogen may result in the
bystander activation of self-reactive cells. For instance, infectious
microbes may damage the tissue and trigger the release of seques-
tered self-antigens, which are normally ignored by the immune
system [30]. The presentation of the released self-antigens along
with the adjuvant effects of the infection can result in the activa-
tion of CNS-speciﬁc, auto-aggressive T cells. Further, the de novo
activation of auto-aggressive immune cells spread the reactivity
against additional self-epitopes, leading to ‘‘epitope spreading’’
[26]. This hypothesis is supported by experimental animal studies
in which TMEV infections led to the spread of autoimmune
responses to additional myelin antigens [31,32]. Bystander activa-
tion of immune cells can also be mediated by inﬂammatory cyto-
kines, superantigens or the innate immune system. Activated,
microbe-speciﬁc T cells secrete numerous cytokines, which can
induce the up-regulation of the expression of MHC molecules as
well as self-antigens. It is known from transgenic models that
the local expression of cytokines and chemokines has pathological
consequences [33]. Another possible mechanism is the activation
of Vb T cell receptor (TCR) chain-expressing T cells by microbial-
derived superantigens. For example, MBP-speciﬁc T cell clones,
which express the Vb8 TCR chain, were shown to be activated by
the bacterial superantigen staphylococcal enterotoxin B [34].
4. Commensal gut microbiota as modulator of CNS
autoimmunity
Despite the long standing interest in pathogenic microbes as
triggers of CNS autoimmunity supported by elegant experimental
models, their involvement in human disease conditions are not
unequivocally established. Recently, the attention has been
re-directed towards resident commensal microbiota as modulator
of CNS autoimmunity.
Humans are colonized by a myriad of microbes, including
bacteria, archaea, fungi, eukaryotes and viruses. They reside in
mucosal surfaces as well as the skin and are collectively termed
microbiota [35]. Different sites of the body harbor their unique
composition of microbial organisms, most of which belong to
two large phyla, the bacteroidetes and the ﬁrmicutes. The microbi-
ota is carrying out important functions beneﬁcial to the host, butRefs.
ein [96]
, DNA polymerase Inﬂuenza type A, hemagglutinin [96]
9–598 [29]
[97]
protein UL86 981–1003 [98]
osphate-binding cassette (ABC) transporter permease 204–217 [99]
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pathology [36].
From recent work, largely performed in the experimental ani-
mal model for MS, experimental autoimmune encephalomyelitis
(EAE), it is becoming clear that the microbial ﬂora contributes sub-
stantially to the CNS-speciﬁc autoimmune disease [37,38]. For
instance, spontaneous EAE incidence was severely reduced in
TCR transgenic mice that were kept in germ-free (GF) conditions
and hence, devoid of resident microbes [39]. Furthermore, EAEFig. 1. Inﬂuence of the gut microbiota on CNS-speciﬁc autoimmunity. The intestinal micr
germ-free conditions) or the alteration of the composition of the intestinal microbial com
inﬂammatory TH1 and TH17 cell populations are reduced, while Treg cells are present in h
Dietary factors play a dual role. While high fat or high salt intake resulted in a higher prop
fatty acids or ﬁbers may establish a gut microbiota, which can suppress CNS autoimmuni
autoimmunity. Through the induction of TH17 cell responses, the segmented ﬁlamentous
bacterium Bacteroides fragilis resulted in the induction of a Treg response, which can supseverity was attenuated in GF mice immunized with myelin pep-
tide antigen in complete Freund’s adjuvant (CFA) [40]. Alterna-
tively, treatment with antibiotics, which induce alterations in the
gut ﬂora, also affected disease severity [41,42]. To date, however,
it is still unclear under which circumstances these ‘beneﬁcial’ bugs
start to play a pathogenic role. Due to the profound impact of the
microbiota on the host’s immune system [36], it can be envisaged
that the microbiota shifts the balance between protective and
pathogenic immune responses (Fig. 1). Indeed, antibiotic-mediatedobiota has profound effects on the immune system. The absence of gut microbes (i.e.
munities through treatment with antibiotics leads to a shift in T cell responses. Pro-
igher numbers and an increase in the production of IL-10 as well as IL-13 was noted.
ortion of intestinal TH17 cells and thus, more severe EAE, vitamins, polyunsaturated
ty. Speciﬁc bacteria or their products can directly inﬂuence the pathogenesis of CNS
bacteria (SFB) exacerbate EAE, while the production of polysaccharide A (PSA) by the
press EAE.
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the pro-inﬂammatory cytokine IL-17 in the gut-associated lym-
phoid tissue, thus altering the function of invariant natural killer
T cells [42]. In addition, antibiotic treatment led to an increase in
the regulatory T (Treg) cell population [41]. Treatment of mice with
the commensal bacteria-derived polysaccharide A (PSA) amelio-
rated EAE symptoms mediated by an increase in the numbers of
Treg cells as well as regulatory B cells [43–45]. On the other hand,
mono-association of GF mice with segmented ﬁlamentous bacteria
(SFB), which were shown to be able to induce TH17 cell-responses,
was sufﬁcient to restore disease susceptibility [46].
Besides the speciﬁc inﬂuence of various gut microbial organ-
isms on the immune system, there is emerging evidence that die-
tary factors may contribute to EAE susceptibility. Gut microbiota
respond to factors introduced by dietary substances either directly
or via the production of metabolites. For example, dietary vitamin
A has notable effects on the induction of Treg cells in the intestinal
mucosa [47] and vitamin D3 confers protection from EAE [48].
Another example is the aryl hydrocarbon receptor (Ahr) and its
ligands. Ahr–ligands are present in cruciferous vegetables and
important for maintaining the intestinal architecture as well as
homeostasis [49]. More recently, it was shown that mice fed a high
fat diet [50] or a high salt diet [51,52] harbored more TH17 cells,
which led to an exacerbation of EAE in these mice.
What are the contributions of the gut ﬂora to MS pathogenesis?
So far, there is no direct evidence supporting a role for the intesti-
nal microbiota neither in the incidence nor in the pathogenesis of
MS. However, several indirect data suggest a potential implication.
This is true, in particular, for dietary factors, which can rapidly alter
gut microbial signatures [53]. Epidemiological studies associate
dietary vitamin D consumption with protection from MS [54], a
notion supported by the genome wide association studies [55].
MS incidence was also positively associated with the consumption
of milk, fat and meat, whereas certain polyunsaturated fatty acids
as well as plant ﬁbers may decrease the risk for development of MS
[56]. Interestingly, recent studies have linked the disease risk to
lifestyle factors that have been shown to interfere with the estab-
lishment of a healthy microbial population in the gastrointestinal
tract, such as early-life antibiotics [57], formula feeding [58] and
caesarian sections [59]. Although the role of the gut microbiota
was not directly investigated in these studies, these lifestyle factors
may hurt the transmission of microbiota, likely leading to aberra-
tions of the intestinal microbial organisms. Another interesting
data showed that the MS disease course was milder in patients
with inﬂammatory bowel disease, who are known to have an
altered gut microbial proﬁle [60].
Mechanistically, the activation of CNS reactive immune cells by
commensal microbiota could be due to molecular mimicry or
bystander activation, similar to the mechanisms proposed for
infectious pathogens. It is theoretically possible that mimicry epi-
topes that resemble CNS antigens are present in the universe of gut
bacterial proteins. However, to our knowledge, no report identify-
ing such a CNS-mimicry epitope derived from gut bacteria has
been published. Instead, the current data favors the bystander acti-
vation hypothesis. It is plausible that the TH17 cells generated in
the intestine are a result of bystander activation of antigen pre-
senting cells, producing cytokines capable of driving naïve T cells
towards pro-inﬂammatory lineages. Recent studies showed that
speciﬁc commensal microbial species are capable of inducing
either IL-17-producing TH17 cells or Treg cells both in the intestine
as well as at peripheral sites [61,62]. The antigen-speciﬁcity of the
microbiota educated T cells is only beginning to be understood.
Most recently, Goto et al. demonstrated that a high frequency of
intestinal TH17 cells recognizes SFB antigens [63]. In the context
of CNS-autoimmunity, mono-association of GF mice with SFB pro-
moted the induction of TH17 cells in TCR transgenic mice (noknown microbial speciﬁcity) as well as in wild type mice harboring
a polyclonal TCR repertoire [39,46].
5. Microbe derived factors in CNS autoimmunity
5.1. Metabolites
The intestinal microbiota produces many ligands, which can
have potential immunomodulatory functions on the CNS. A nota-
ble example for such dietary metabolites is the short chain fatty
acids (SCFAs), acetate, butyrate or propionate. SCFAs are a
byproduct of the fermentation of plant polysaccharides by intes-
tinal microbes [64] and serve as a source of energy for colonic
epithelial cells, but are detectable in the blood [65]. SCFAs exert
their anti-inﬂammatory functions through binding to speciﬁc
G-protein coupled receptors (GPRs). Engagement of GPR43, for
example, ameliorates colitis [66]. However, their beneﬁcial effects
are not solely restricted to the gut, since SCFAs can positively
inﬂuence diseases remote to the intestine, such as arthritis or
asthma [66,67]. Besides binding to GPRs, SCFAs can mediate their
beneﬁcial function through the inhibition of histone deacetylases,
which lead to the induction of Treg cells or the suppression of the
production of pro-inﬂammatory cytokines by antigen presenting
cells [68–70]. A recent study reported a potential connection
between SCFAs and the CNS, showing that propionate can activate
the gut-brain neural circuit, which had beneﬁcial effects on the
host physiology. Whether SCFAs also exhibit a beneﬁcial role in
CNS autoimmunity has yet to be determined. Many byproducts
of the gut microbiota metabolism could have an impact on the
immune system and may thereby modulate autoimmune
responses. Another example is the commensal bacteria-derived
ATP, which was demonstrated to support the induction of pro-
inﬂammatory TH17 cells in the intestine [71]. These TH17 cells
may populate peripheral immune organs and thereby, drive
CNS-speciﬁc autoimmunity [38].
5.2. Microbial products
In addition to metabolites, microbial products are effective
components of the microbial communication with the CNS. The
gut microbiota harbors many ligands that are sensed by the
immune system and could potentially contribute to CNS autoim-
munity. This has been extensively shown for the zwitterionic cap-
sular PSA, which is derived from the human gut commensal
Bacteroides fragilis. PSA conditions dendritic cells in a way that
facilitates the differentiation of T cells towards TH1 cells, IL-10-pro-
ducing T cells or Treg cells [43,72,73] and thus, results in an efﬁcient
suppression of MOG-peptide induced EAE [43,45]. Microbial lipids
could also serve as a potential messenger in the microbe-host-
interactions. A recent study identiﬁed a serine-containing lipodi-
peptide, Lipid 654, as a biomarker for MS. The lipid 654, which is
produced by a number of Bacteroidetes species, is present at lower
levels in the serum of MS patients compared to healthy controls
[74]. Notably, Lipid 654 is a ligand for human and mouse Toll like
receptor (TLR) 2 [75]. It is possible that the microbial ligands,
entering the systemic circulation, could serve as immunoregula-
tory factors and that the low level tonic signaling induced by the
microbial products may set an activation threshold for the host’s
immune system [76].
The microbial products (heat killed Mycobacterium tuberculosis)
that are administered together with CFA are essential components
for the induction of EAE in experimental animals [77]. These path-
ogen associated molecular patterns (PAMPs) activate signaling
pathways in innate immune cells and T cells, breaking immune tol-
erance and thus, facilitating CNS autoimmunity [78]. Indeed,
Myd88-deﬁcient mice, which are defective in TLR- and IL-1
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tant to EAE induction [79,80]. Resistance to EAE is due to the defec-
tive IL-6 and IL-23 production by dendritic cells to efﬁciently prime
TH1 and TH17 responses [79,80]. Different experimental models
suggest a role for distinct TLR mediated signaling pathways in
EAE induction or suppression. For example, injection of ligands
for TLR9 or TLR4 overcame the EAE resistance in TCR transgenic
B10.S mice by activating antigen presenting cells [81]. Similarly,
administration of TLR2/Dectin-1 and TLR4 ligands supported the
induction of the disease [82,83]. On the other hand, activation of
TLR3 via polyI:C suppressed EAE through the production of inter-
feron b [84]. In addition to activating innate immune cells, T cell
intrinsic TLR signaling can affect T cell differentiation, contributing
to CNS autoimmunity [85,86].
The bacterial cell wall component peptidoglycan (PGN), an
important bacterial ligand, has also been implicated in chronic
inﬂammation. PGN is sensed by several receptors of the innate
immune system, such as the TLR2, Nod 1 or peptidoglycan recogni-
tion proteins [87]. PGN from Gram-negative bacteria can translo-
cate across the gut mucosa to enhance systemic immunity [88].
Although the highest load of PGN is detected at mucosal sites,
PGN is also present in the blood, liver as well as in lymphoid
tissues [89–92]. Interestingly, high numbers of PGN-containing
dendritic cells and macrophages with enhanced expression of
co-stimulatory molecules were found in brain tissue from MS
patients and in non-human primate EAE models [93,94]. PGN acts
as an adjuvant by stimulating dendritic cell maturation as well as
cytokine production by T cells and was sufﬁcient to replace CFA
[95]. It is likely that commensal bacteria derived TLR ligands or
PGN plays a similar role in CNS autoimmunity, however, direct
evidence is still lacking.6. Future directions and concluding remarks
Over the years, we gained enormous insight into the patho-
mechanisms contributing to CNS autoimmunity. Inﬂammatory
processes are important during the early phases of the disease
and an arsenal of approved therapeutic substances aims to target
these inﬂammatory components of MS. However, despite all these
advances, our understanding of the triggers of CNS autoimmunity
is still at infancy. Emerging evidence demonstrates that microbial
agents – both pathogenic and commensal – remain a potential trig-
ger of MS. In particular, the contribution of the commensal micro-
biota to disease pathogenesis is intriguing. We are witnessing an
exponential rise in microbiome associations with many human
diseases. Comprehensive and coordinated efforts will be needed
to understand the links between microbial agents and CNS
autoimmunity.
However, there are a number of barriers to be overcome to
make a conclusive argument for a causal connection between
CNS autoimmunity and commensal organisms. First, we should
identify CNS autoimmunity triggering/protecting commensal
microbial proﬁles. The ever improving ‘omics’ technologies in char-
acterizing the microbial community’s composition and functions
will be pivotal in our quest in the identiﬁcation of speciﬁc micro-
bial species associated with CNS autoimmunity. Second, we face
a great challenge in translating pre-clinical ﬁndings to human
autoimmune conditions. Basic research studies in inbred animals
have taken a great leap in unraveling the molecular underpinnings
of the microbiota in the host physiology. While a clear association
between the microbiota and CNS autoimmunity could be estab-
lished in animal models, so far, there is no published report
describing the microbial composition of patients suffering from
CNS autoimmunity. Third, methodologies to prove the up-coming
associations shown by deep-sequencing data from human patientsmust be developed. In particular, the spontaneously developing
autoimmune mouse models will be pivotal in proving these asso-
ciations. For example, the patient derived microbial samples could
be associated with autoimmune prone mice to verify their disease
modulating potential. Fourth, we should improve our understand-
ing how gut microbiota can potentially inﬂuence organs far away
from the intestine. In addition to activating the immune system
through direct interactions, the bacteria in the gut are able to pro-
duce a plethora of small molecule metabolites, collectively termed
the metabolome. We must identify important metabolic products
which have critical roles in communicating microbial abundance
and composition to the host. Clearly, as the ﬁeld increasingly
adopts new multidimensional approaches, we are on the verge of
an exciting new era for resident microbiota and CNS
autoimmunity.
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